
Covid is still around and a risk to vulnerable people; here are the symptoms to look out for in 2025
Five years ago, COVID was all we could think about. Today, we'd rather forget about lockdowns, testing queues and social distancing. But the virus that sparked the pandemic, SARS-CoV-2, is still circulating.
Most people who get COVID today will experience only a mild illness. But some people are still at risk of severe illness and are more likely to be hospitalised with COVID. This includes older people, those who are immunocompromised by conditions such as cancer, and people with other health conditions such as diabetes.
Outcomes also tend to be more severe in those who experience social inequities such as homelessness. In the United Kingdom, people living in the 20% most deprived areas have double chance of being hospitalised from infectious diseases than those in the least deprived areas.
In Australia, 58,000 COVID cases have been reported so far in 2025. However, testing rates have declined and not all positive cases are reported to the government, so case numbers in the community are likely much higher.
Latest data from FluCan, a network of 14 hospitals, found 781 people were hospitalised for COVID complications in the first three months of the year. This 'sentinel surveillance' data gives a snapshot from a handful of hospitals, so the actual number of hospitalisations across Australia is expected to be much higher.
While deaths are lower than previous years, 289 people died from COVID-related respiratory infections in the first two months of the year.
What can we expect as we head into winter? We often see an increase in respiratory infections in winter.
However, COVID peaks aren't just necessarily seasonal. Over the past few years, peaks have tended to appear around every six months.
What are the most common COVID symptoms? Typical early symptoms of COVID included fever, cough, sore throat, runny nose and shortness of breath. These have remained the most common COVID symptoms across the multiple variant waves.
Early in the pandemic, we realised COVID caused a unique symptom called anosmia – the changed sense of taste or smell. Anosmia lasts about a week and in some cases can last longer. Anosmia was more frequently reported from infections due to the ancestral, Gamma, and Delta variants but not for the Omicron variant, which emerged in 2021.
However, loss of smell still seems to be associated with some newer variants. A recent French study found anosmia was more frequently reported in people with JN.1.
But the researchers didn't find any differences for other COVID symptoms between older and newer variants.
Yes. Testing is particularly important if you experience COVID-like symptoms or were recently exposed to someone with COVID and are at high-risk of severe COVID. You might require timely treatment.
If you are at risk of severe COVID, you can see a doctor or visit a clinic with point-of-care testing services to access confirmatory PCR (polymerase chain reaction) testing.
Rapid antigen tests (RATs) approved by Australia's regulator are also still available for personal use.
But a negative RAT doesn't mean that you don't have COVID – especially if you are symptomatic.
If you do test positive, while you don't have to isolate, it's best to stay at home.
If you do leave the house while experiencing COVID symptoms, minimise the spread to others by wearing a well-fitted mask, avoiding public places such as hospitals and avoiding contact with those at higher risk of severe COVID.
In most people with mild to moderate COVID, it can last 7–10 days.
Symptomatic people can spread the infection to others from about 48 hours before you develop symptoms to about ten days after developing symptoms. Few people are infectious beyond that. But symptoms can persist in more severe cases for longer.
A UK study which tracked the persistence of symptoms in 5,000 health-care workers found symptoms were less likely to last for more than 12 weeks in subsequent infections.
General fatigue, for example, was reported in 17.3% of people after the first infection compared with 12.8% after the second infection and 10.8% following the third infection.
Unvaccinated people also had more persistent symptoms.
Vaccinated people who catch COVID tend to present with milder disease and recover faster. This may be because vaccination prevents over-activation of the innate immune response.
Vaccination remains the best way to prevent COVID Vaccination against COVID continues to be one of the most effective ways to prevent COVID and protect against it. Data from Europe's most recent winter, which is yet to be peer reviewed, reports COVID vaccines were 66% effective at preventing symptomatic, confirmed COVID cases.
Most people in Australia have had at least one dose of the COVID vaccine. But if you haven't, people over 18 years of age are recommended to have a COVID vaccine.
Boosters are available for adults over 18 years of age. If you don't have any underlying immune issues, you're eligible to receive a funded dose every 12 months.
Boosters are recommended for adults 65–74 years every 12 months and for those over 75 years every six months.
Adults over 18 years who are at higher risk because of weaker immune systems are recommended to get a COVID vaccine every 12 months and are eligible every six months.
A new review of more than 4,300 studies found full vaccination before a SARS-CoV-2 infection could reduce the risk of long COVID by 27% relative to no vaccination for the general adult population.
With ongoing circulation of COVID, hybrid immunity from natural infection supplemented with booster vaccination can help prevent large-scale COVID waves.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New Indian Express
39 minutes ago
- New Indian Express
70 per cent of WHO's total vaccines are sourced from India: Minister Anupriya Patel
NEW DELHI: India continues to be a leading supplier of vaccines and as much as 70 percent of World Health Organisation's total vaccines are sourced from the country, the Centre said on June 16. '..India has emerged as a global hub for affordable healthcare solutions and continues to deepen its partnerships with nations through knowledge-sharing, capacity-building, and health diplomacy,' said Union Minister of State for Health and Family Welfare and Chemicals and Fertilizers Anupriya Patel. Delivering the keynote address at the inaugural session of Second Policymakers' Forum, which aims to strengthen global collaboration on drug standards and access to affordable medicines, she emphasised India's commitment to ensuring equitable access to quality-assured medicines. The minister also stressed the importance of regulatory harmonisation in facilitating global health equity. She also recalled that during the COVID-19 pandemic, India started the 'Vaccine Maitri' initiative and supplied vaccines to more than 100 friendly countries, which depicts India's deep sense of responsibility towards global health and its intention of helping friendly countries in times of distress.
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
70% vaccines sourced by WHO are from India; US imports 14% generics
Union Minister of State for Health Anupriya Patel said on Monday 70 per cent of total vaccines sourced by the World Health Organization (WHO) and 14 per cent of generics imported by the US are from India. She delivered the keynote address at the inaugural session of the Second Policymakers' Forum organised by the Indian Pharmacopoeia Commission (IPC) here. An international delegation of policymakers and drug regulators from 24 countries is participating in the forum. Aimed at promoting the recognition of the Indian Pharmacopoeia and collaboration in India's initiative for flagship affordable medicines -- the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) -- the Forum is being organised by the IPC under the aegis of the Ministry of Health and Family Welfare in association with the Ministry of External Affairs. In her keynote address, Patel emphasised India's commitment to ensuring equitable access to quality-assured medicines and stressed the importance of regulatory harmonisation in facilitating global health equity. She also highlighted that "under the visionary leadership of Prime Minister Shri Narendra Modi, India has emerged as a global hub for affordable healthcare solutions and continues to deepen its partnerships with nations through knowledge-sharing, capacity-building and health diplomacy". Underlining the importance of the Jan Aushadi Kendras, Patel said, "Our Jan Aushadhi Kendras are the shining examples of India's commitment to provide quality and affordable medicines to all our citizens. Jan Aushadhi has been one of the most powerful instruments of bringing down the out-of-pocket expenditure of our citizens." Highlighting India's strides made in the direction of providing vaccines, Patel said India continues to be a leading supplier of vaccines. "As much as 70 per cent of WHO's total vaccines are sourced from India," she said. She said during the COVID-19 pandemic, India started the 'Vaccine Maitri' initiative and supplied vaccines to more than 100 friendly countries, which depicts India's deep sense of responsibility towards global health and its intention of helping friendly countries in times of distress. Patel said, "India continues to be a leader in drug manufacturing, especially when it comes to generic medicines. 14 per cent of generics imported by the US come from India while India also has the maximum number of US FDA (Food and Drug Administration) recognized drug manufacturing plants." She further underlined that "70% of our generics are exported to the highly regulated markets and our pharmacopeial regulations are regularly visited to meet the global benchmarks". Patel said, "We have retained the WHO's Global Benchmarking Tool (GBT) framework, Maturity Level 3 (ML3) status which reflects the robustness of India's regulatory framework. Presently, 15 countries in the world recognise Indian Pharmacopeia as a book of standards for drugs, Cuba recently becoming the 15th country to recognise the Indian Pharmacopeia." She said it is not just a regulatory step but a move towards bringing more alignment in the quality standards, expanding access to safe and effective drugs and making trade in pharmaceuticals smoother than ever before. Patel reaffirmed that "we are committed to helping our partner countries by way of communicating and planning" and "hope to continue to work together to advance the regulatory collaboration and promote the recognition of the pharmacopeial standards so that we can strive fast towards the shared goal of 'Health for All'".


Deccan Herald
2 hours ago
- Deccan Herald
ED issues fresh summons to Robert Vadra in Sanjay Bhandari linked PMLA case
Vadra (56), was called for questioning in the case on June 10 but he skipped, saying he had flu-like symptoms on June 9 and had undertaken a Covid test as per protocol.